Previous 10 | Next 10 |
Calxyt, Inc. Announces Pricing of $10.9 Million SEC-Registered Offering of Common Stock and Warrants PR Newswire ROSEVILLE, Minn. , Feb. 17, 2022 /PRNewswire/ -- Calyxt, Inc. (NASDAQ: CLXT) ("Calyxt" or the "Company"), a plant-based synthetic biology company, tod...
Calyxt Announces Gerry Nuovo as Senior Vice President of Business Development PR Newswire ROSEVILLE, Minn. , Feb. 7, 2022 /PRNewswire/ -- Calyxt, Inc. (Nasdaq: CLXT), a plant-based synthetic biotechnology company, today announced that Gerry Nuovo has ...
Calyxt Announces Pilot BioFactory™ Production System Now Operational PR Newswire ROSEVILLE, Minn. , Jan. 6, 2022 /PRNewswire/ -- Calyxt, Inc. (Nasdaq: CLXT), a plant-based synthetic biotechnology company, today announced that its pilot BioFactory...
Calyxt to Present at the H.C. Wainwright BioConnect Virtual Conference PR Newswire ROSEVILLE, Minn. , Jan. 4, 2022 /PRNewswire/ -- Calyxt, Inc. (Nasdaq: CLXT), a plant-based synthetic biotechnology company today announced that a presentation given by mana...
Calyxt Identifies More Than 15,000 Unique Chemical Signatures in Lab-Scale BioFactory™ Production Run - Represents significant progress in sustainable discovery and development of plant-based molecules in Calyxt's BioFactory - Forms a baseline library of chemistries a...
Calyxt to Present at the 2021 Canaccord Genuity AgriFood Tech Innovation Virtual Forum PR Newswire ROSEVILLE, Minn. , Nov. 23, 2021 /PRNewswire/ -- Calyxt, Inc. (Nasdaq: CLXT), a plant-based synthetic biotechnology company, today announced that management...
Calyxt (NASDAQ:CLXT): Q3 Non-GAAP EPS of -$0.24 misses by $0.05; GAAP EPS of -$0.20 misses by $0.01. Revenue of $7.76M (+48.1% Y/Y) beats by $3.54M. Shares -1.23%. Press Release For further details see: Calyxt EPS misses by $0.05, beats on revenue
Calyxt Reports Third Quarter 2021 Financial Results -Announced new strategic direction to provide sustainably produced plant-based synthetic biology solutions to expanded group of end markets and diversified base of customers, leveraging its proprietary PlantSpring™ Techn...
Calyxt (NASDAQ:CLXT) is scheduled to announce 3Q earnings results on Thursday, November 4th, after market close. The consensus EPS Estimate is -$0.16 (+42.9% Y/Y) and the consensus Revenue Estimate is $4.33M (-17.4% Y/Y). Over the last 1 year, CLXT has beaten EPS estimates 25% of the time and...
Some of the best penny stocks 2021 has offered were some of the most unassuming at the beginning of their epic runs. For instance, stocks like Vinco Ventures ( NASDAQ:BBIG ), Camber Energy ( NYSE:CEI ), and even AMC Entertainment ( NYSE:AMC ) all began trending quietly among sma...
News, Short Squeeze, Breakout and More Instantly...
Shares of Calyxt, Inc. (NASDAQ: CLXT) traded at a new 52-week high today and are currently trading at $5.4. So far today, approximately 55,181 shares have been exchanged, as compared to an average 30-day volume of 89,248 shares. Calyxt, Inc., a synthetic biology company, engages in delivering...
Calyxt Announces Stockholder Approval of Merger With Cibus PR Newswire -- Calyxt Announces 1-for-5 Reverse Stock Split of Common Stock -- ROSEVILLE, Minn. , May 19, 2023 /PRNewswire/ -- Calyxt, Inc. (Nasdaq: CLXT) ("Calyxt" or the "Company") today announc...
Calyxt Reports First Quarter 2023 Financial Results and Provides Corporate Update PR Newswire —P roposed merger with Cibus Global Expected to Close in Q2 2023 — —1-for-10 reverse stock split executed— —Current customer...